AspenBio Pharma to Present at the 28th Annual Canaccord Adams Global Growth Conference
CASTLE ROCK, CO--(Marketwire - August 5, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an
emerging bio-pharmaceutical company dedicated to the development of novel
drugs and diagnostics for animals and humans, has been invited to present
at the 28th Annual Canaccord Adams Global Growth Conference to be held at
the InterContinental Boston on August 12-14, 2008.
AspenBio president and CEO, Richard G. Donnelly, is scheduled to present on
Thursday, August 14 at 9:30 a.m. Eastern Time. The presentation will be
available via webcast at
http://www.corporateir.net/ireye/conflobby.zhtml?ticker=APPY&item_id=1887826.
Mr. Donnelly will discuss the continued advancement of AppyScore™, the
world's first blood-based screening/triage test for human appendicitis. The
company is currently conducting an 800 patient FDA clinical trial in
preparation for a late 2008 FDA 510(k) filing. He will also update on the
exclusive license and commercialization agreement AspenBio recently signed
with Novartis Animal Health, Inc. for the development and worldwide launch
of AspenBio's novel bovine reproduction drugs, BoviPure LH™ and BoviPure
FSH™.
About Canaccord Adams
Canaccord Adams is a leading independent financial services firm committed
to fostering the entrepreneurial economy by bringing corporate and
institutional clients unique perspective on global investment
opportunities. With operations in research, sales and trading, and
investment banking, Canaccord's 225 professionals seek out emerging
opportunities in the key sectors of Mining and Metals, Energy, Technology,
Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth.
Located in eight offices internationally, Canaccord's experienced team
generates focused, actionable ideas that identify opportunity and
facilitate growth.
About AspenBio Pharma, Inc.
AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the
discovery; development, manufacture, and marketing of novel proprietary
products, including those that enhance the reproductive efficiency of
animals and that have large worldwide market potential. The company was
originally formed to produce purified proteins for diagnostic applications
and has become a leading supplier of human hormones to many of the nation's
largest medical diagnostic companies and research institutions. The company
has successfully leveraged this foundational science and technology
expertise to rapidly develop an enviable late-stage pipeline of several
novel reproduction hormone analogs for wide-ranging therapeutic use in
animals of economic importance. AspenBio Pharma continues to advance the
development and testing of its two first-generation blood-based human
diagnostic tests designed to rapidly help diagnose or rule out acute
appendicitis in patients complaining of abdominal pain. For more
information, go to www.aspenbiopharma.com.
Forward-Looking Statements
This news release includes "forward-looking statements" of AspenBio Pharma,
Inc. ("APPY") as defined by the Securities and Exchange Commission (the
"SEC"). All statements, other than statements of historical fact, included
in the press release that address activities, events or developments that
APPY believes or anticipates will or may occur in the future are
forward-looking statements. These statements are based on certain
assumptions made based on experience, expected future developments and
other factors APPY believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of APPY. Investors are cautioned that
any such statements are not guarantees of future performance. Actual
results or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including
statements regarding the ability to successfully complete the development
of, obtain FDA approval for, cost effectively manufacture and generate
revenues from the appendicitis test as well as the animal products under
this agreement and other new products, execute agreements required to
successfully advance the company's objectives, retain the scientific
management team to advance the products, overcome adverse changes in market
conditions and the regulatory environment, fluctuations in sales volumes,
obtain and enforce intellectual property rights, and realization of
intangible assets. Furthermore, APPY does not intend (and is not obligated)
to update publicly any forward-looking statements. The contents of this
news release should be considered in conjunction with the warnings and
cautionary statements contained in APPY's recent filings with the SEC.